<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19654941</article-id><article-id pub-id-type="doi">10.3346/jkms.2009.24.4.614</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Interleukin-13 and Its Receptors in Idiopathic Interstitial Pneumonia: Clinical Implications for Lung Function</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Park</surname><given-names>Sung-Woo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Mi-Hyun</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jang</surname><given-names>Hee Kyung</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jang</surname><given-names>An Soo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Do-Jin</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Koh</surname><given-names>Eun-Suk</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jong-Sook</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Uh</surname><given-names>Soo-Taek</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Yong Hoon</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jai Soung</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Paik</surname><given-names>Sang Hyun</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>Hwa-Kyun</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Youm</surname><given-names>Wook</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Park</surname><given-names>Choon-Sik</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Genome Research Center for Allergy and Respiratory Disease, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.</aff><aff id="A2"><label>2</label>Department of Pathology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.</aff><aff id="A3"><label>3</label>Department of Radiology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.</aff><aff id="A4"><label>4</label>Department of Thoracic Surgery, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.</aff><author-notes><corresp> Address for correspondence: Choon-Sik Park, M.D. Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, 1174 Jung-dong, Wonmi-gu, Bucheon 420-020, Korea. Tel: +82.32-621-5105, Fax: +82.32-621-5023, <email>mdcspark@unitel.co.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>29</day><month>7</month><year>2009</year></pub-date><volume>24</volume><issue>4</issue><fpage>614</fpage><lpage>620</lpage><history><date date-type="received"><day>07</day><month>3</month><year>2008</year></date><date date-type="accepted"><day>04</day><month>8</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 The Korean Academy of Medical Sciences</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Idiopathic interstitial pneumonia (IIP) is characterized by varying degrees of interstitial fibrosis. IL-13 and IL-4 are strong inducers of tissue fibrosis, whereas IFN-&#x003b3; has antifibrotic potential. However, the roles of these substances in IIP remain unknown. IL-13, IL-4, and IFN-&#x003b3; were measured in the BAL fluid of 16 idiopathic pulmonary fibrosis (IPF) patients, 10 nonspecific interstitial pneumonia (NSIP) patients, and 8 normal controls. The expression of IL-13 and IL-13R&#x003b1;1/&#x003b1;2 in lung tissues was analyzed using ELISA and immunohistochemistry. IL-13 levels were significantly higher in IPF patients than the others (<italic>P</italic>&#x0003c;0.05). IL-4 levels were higher in both IPF and NSIP patients than in normal controls (<italic>P</italic>&#x0003c;0.05), and IFN-&#x003b3; levels were lower in NSIP patients than in normal controls (<italic>P</italic>=0.047). IL-13 levels correlated inversely with FVC% (r=-0.47, <italic>P</italic>=0.043) and DLCO% (r=-0.58, <italic>P</italic>=0.014) in IPF and NSIP patients. IL-13 was strongly expressed in the smooth muscle, bronchial epithelium, alveolar macrophages and endothelium of IPF patients. IL-13R&#x003b1;1, rather than IL-13R&#x003b1;2, was strongly expressed in the smooth muscle, bronchial epithelium, and endothelium of IPF patients. IL-13 and its receptors may contribute to the pathogenesis of fibrosis in IIP and appear to be related to the severity of the disease.</p></abstract><kwd-group><kwd>Interleukin-13</kwd><kwd>Interleukin-13 Receptor Alpha1 Subunit</kwd><kwd>Interleukin-13 Receptor Alpha2 Subunit</kwd><kwd>Idiopathic Pulmonary Fibrosis</kwd><kwd>Lung Function</kwd><kwd>NSIP</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Idiopathic pulmonary fibrosis (IPF) is a progressive and usually lethal lung disease characterized by fibroblast proliferation and extracellular matrix accumulation (<xref ref-type="bibr" rid="B1">1</xref>). Its pathogenesis remains poorly understood but is associated with a predominance of Th2 cytokine and a paucity of Th1 cytokine (<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>). Studies on immunopathology (<xref ref-type="bibr" rid="B2">2</xref>) and m-RNA expression (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>) have revealed that the lung tissues of IPF patients show abnormally high levels of interleukin (IL)-4 and IL-5, and a low level of interferon-&#x003b3; (IFN-&#x003b3;). Flow cytometry analysis of intracellular cytokines showed a similar pattern in the bronchoalveolar lavage (BAL) cells of IPF patients (<xref ref-type="bibr" rid="B5">5</xref>). The role of Th2 cytokines, especially IL-4 and IL-13, in pulmonary fibrosis has been clearly demonstrated by both in vivo and in vitro experiments (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). These two cytokines function via complex receptor systems that include IL-4 receptor alpha (IL-4R&#x003b1;), and IL-13 receptor alpha1 (IL-13R&#x003b1;1) (<xref ref-type="bibr" rid="B8">8</xref>). IL-13R&#x003b1;1 binds IL-13 in a complex with IL-4R&#x003b1;1 (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). IL-13 receptor &#x003b1;2 (IL-13R&#x003b1;2) has a short cytoplasmic tail without intracellular signaling motifs; thus, it may function as a decoy receptor that inhibits the effects of IL-13 (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). The down-regulatory effect of IL-13R&#x003b1;2 has been demonstrated in animal models with IL-13-mediated tissue fibrosis (<xref ref-type="bibr" rid="B12">12</xref>) but has not been shown in humans.</p><p>IPF and nonspecific interstitial pneumonia (NSIP) are the two common types of idiopathic interstitial pneumonia (IIP). However, compared with IPF, NSIP leads to less fibrosis (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>) and shows a better response to anti-inflammatory agents such as steroids and anti-proliferative drugs (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Therefore, the two diseases may induce different patterns of fibrosis-related cytokines. It has already been demonstrated that NSIP and IPF lead to different levels of inflammatory cytokines and CXC chemokines, such as IL-6, IL-8, epithelial neutrophil-activating peptide 78, interferon gamma-inducible protein 10, RANTES, and monocyte chemotactic protein-1 (<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B20">20</xref>), but little is known about how Th2 and Th1 cytokines and their receptors differ between the two conditions.</p><p>We hypothesized that IFN-&#x003b3;, IL-4, and IL-13 may be regulated differently and that IL-13R&#x003b1;1 and IL-13R&#x003b1;2 may be expressed differently in IPF and NISP patients.</p><p>To test this hypothesis, we measured IL-4, IL-13, and IFN-&#x003b3; levels in the BAL fluid of IPF and NSIP patients and normal controls, and compared IL-13R&#x003b1;1 and IL-13R&#x003b1;2 expression in diseased lung tissues using immunohistochemical staining.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Study populations</title><p>The study population consisted of 16 patients with IPF, ten with idiopathic NSIP, and eight normal controls. All subjects were given a chest radiograph, HRCT, pulmonary function test, and blood gas analysis (<xref ref-type="table" rid="T1">Table 1</xref>). The diagnoses of IPF and NSIP were based on the international consensus statement (<xref ref-type="bibr" rid="B21">21</xref>). Two of the NSIP patients had inflammation and fibrotic type pneumonia (group II) and eight had interstitial fibrotic type pneumonia (group III). BAL and open -lung or video-guided thoracoscopic biopsies were performed on all IIP patients. BAL was performed at least 3 days before lung biopsy and without any immunosuppressive therapies. In normal subjects, BAL was performed on the right middle lobe. Exclusion criteria consisted of other known causes of interstitial lung disease, such as drug reactions, environmental exposures, and collagen vascular diseases. The normal controls were all healthy volunteers, free of symptoms, not taking any medications, and who had normal chest radiographs. For immunohistochemical staining, the healthy tissues of biopsies of solitary pulmonary nodules were used.</p></sec><sec><title>Measurements of IL-13, IL-4, and IFN-&#x003b3; concentrations in Bronchoalveolar lavage (BAL) fluids</title><p>BAL was performed as previously described (<xref ref-type="bibr" rid="B17">17</xref>), using a flexible fiberoptic bronchoscope (Olympus B2-10; Olympus Optical Co., Tokyo, Japan). Briefly, all study subjects were pretreated with atropine (0.5 mg) immediately before the BAL procedure. Bronchial trees were instilled four times with 50 mL of normal saline, and fluid was removed each time by gentle suction with negative pressure below 50 mmHg. The total volume of recovered fluids was measured, and the supernatant was separated from the cell pellets by centrifugation at 500&#x000d7;g for 5 min. The supernatants were frozen and stored at -80&#x02103; for later use. A differential count of 500 cells was performed on slides prepared by cytocentrifugation and Diff-Quik staining (Scientific Products, Gibbstowne, NJ, U.S.A.). No complications were experienced during the BAL procedures.</p><p>The IL-13, IL-4, and IFN-&#x003b3; levels were measured using quantitative sandwich enzyme immunoassays with ELISA kits (BD Bioscience, San Diego, CA, U.S.A.), according to the manufacturer's recommendations. The detection limits were 2.0 pg/mL, 3.5 pg/mL, and 1.0 pg/mL for IL-4, IL-13, and IFN-&#x003b3;, respectively, and values below these thresholds were assigned a value of 0 pg/mL. For validation of assay, we performed spiking experiment using 10 samples and the recovery rates of IL-4, IL-13, and IFN-&#x003b3; were 86.2&#x000b1;0.1%, 93.5&#x000b1;0.6%, 89.3&#x000b1;0.8%, respectively. The inter-assay coefficient of variability for all assays was less than 10%, and the intraassay coefficient of variability was less than 10% across the range of concentrations.</p></sec><sec><title>Immunohistochemical staining</title><p>A VectaStatin goat ABC Elite kit (Vector Laboratories, Burlingame, CA, U.S.A.) was used for immunostaining. Tissue sections (5 &#x000b5;m) were deparaffinized, endogenous peroxidase was blocked with 1.4% H<sub>2</sub>O<sub>2</sub> in MeOH for 30 min, and nonspecific binding was blocked with 1.5% normal rabbit serum for 30 min. The sections were incubated with goat polyclonal antihuman IL-13 antibody (1:100, Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) and goat polyclonal antihuman IL-13R&#x003b1;1 and IL-13R&#x003b1;2 antibody (1:200, R&#x00026;D, Minneapolis, MN, U.S.A.) at 4&#x02103; for 16 hr. After washing with TBS, the sections were sequentially incubated with biotinylated rabbit anti-goat immunoglobulin G (H+L) (1:200, Vector Laboratories, Burlingame, CA, U.S.A.) and avidin-biotin peroxidase complex (1:50, ABC kit, Vector Laboratories) for 30 min. The color reaction was developed with 3,3'-diaminobenzidine tetrachloride (Zymed Laboratories, South San Francisco, CA, U.S.A.), and Harris hematoxylin stain was applied as a counter stain. The intensity of immunostaining was graded from absent (-) to strongly positive (+++) for the following tissues: alveolar epithelium, bronchial epithelium, smooth muscle, alveolar macrophage, endothelial cells, and interstitium. Grading was as follows: (-), no staining; (&#x000b1;), very faintly brown; (+), faintly brown; (++), moderately brown; and (+++), dark brown. Histological sections were assessed independently by two observers who were blind to the clinical information of the study subjects.</p></sec><sec><title>Statistics</title><p>The SPSS/PC+ program (Chicago, IL, U.S.A.) was used for statistical analyses. Differences between groups were compared with the nonparametric Kruskal-Wallis test for continuous data. Significant relationships between groups were further analyzed using the Mann-Whitney U test. Spearman's rank correlation was used to analyze the relationships of IL-4, IL-13, and IFN-&#x003b3; concentrations to the lung functions. Differences were considered significant at <italic>P</italic>&#x0003c;0.05. The data are expressed as mean&#x000b1;SEM.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Clinical profiles of study subjects and cellular proportions in BAL fluids</title><p>The clinical and BAL profiles are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. Age, smoking status, and sex ratio were comparable among the three groups. The NSIP and IPF patients had a significant reduction in forced vital capacity (FVC), total lung capacity (TLC), and diffusing capacity of carbon monoxide (DLCO) compared with controls (<italic>P</italic>&#x0003c;0.05). Both the cell number and percentage of neutrophils in 1 mL of BAL fluid were significantly higher in patients with NSIP and in those with IPF than in control subjects (<italic>P</italic>&#x0003c;0.01 and <italic>P</italic>&#x0003c;0.05, respectively). There were no difference in the percentages of lymphocytes and macrophages between NSIP and IPF patients, but IPF patients had a significantly higher percentage of eosinophils than controls (<italic>P</italic>&#x0003c;0.01).</p></sec><sec><title>IL-4, IL-13, and IFN-&#x003b3; concentrations in BAL fluids</title><p>IL-13 activity was detected in the BAL fluid of all patients and in seven of the eight control subjects. The IL-13 levels were higher in IPF patients than in NSIP patients (249.0&#x000b1;83.1 vs. 137.7&#x000b1;37.9 pg/mL, <italic>P</italic>=0.032) and controls (249.0&#x000b1;83.1 vs. 49.0&#x000b1;13.1 pg/mL, <italic>P</italic>=0.012). The IL-13 levels were also higher in NSIP patients than in controls (<italic>P</italic>=0.041; <xref ref-type="fig" rid="F1">Fig. 1A</xref>). IL-4 activity was detected in 12 of 16 IPF patients, eight of ten NSIP patients, and three of eight controls. The mean IL-4 level was significantly higher in the IPF and NSIP groups than in the control group (16.3&#x000b1;4.5 and 12.3&#x000b1;3.35 pg/mL vs. 4.67&#x000b1;2.28 pg/mL, <italic>P</italic>=0.008 and <italic>P</italic>=0.034, respectively). The IL-4 level was not significantly different between the IPF and NSIP groups (<italic>P</italic>&#x0003e;0.05; <xref ref-type="fig" rid="F1">Fig. 1B</xref>). IFN-&#x003b3; activity was detected in 14 of 16 IPF patients, nine of ten NSIP patients, and seven of eight controls. Both patient groups had low INF-&#x003b3; levels compared with the control group (7.72&#x000b1;3.02 and 3.82&#x000b1;1.59 pg/mL vs. 11.32&#x000b1;3.64 pg/mL; <xref ref-type="fig" rid="F1">Fig. 1C</xref>), but only the difference between NSIP patients and controls was significant (<italic>P</italic>=0.047). The IL-13 level was inversely correlated with DLCO (% pred) (n=26, r=-0.58, <italic>P</italic>=0.014) and FVC (% pred) (n=26, r=-0.47, <italic>P</italic>=0.043) in NSIP and IPF patients (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Neither the IL-4 nor INF-&#x003b3; level correlated with the physiological parameters (data not shown).</p></sec><sec><title>Expression of IL-13 and IL-13R&#x003b1;1/&#x003b1;2 detected by immunohistochemical staining</title><p>Immunohistochemical staining of IL-13, IL-13R&#x003b1;1, and IL-13R&#x003b1;2 was performed in the lung tissues of controls (n=4), IPF patients (n=6), and NSIP patients showing fibrosis (n=6). To avoid the smoking effect, never smokers were selected from the study subjects. Control subjects had undergone a lobectomy to remove localized solitary pulmonary nodules (two lung cancer and two tuberculoma). Both IL-13 and IL-13R&#x003b1;1 were strongly expressed in the bronchial epithelial cells, alveolar macrophages, endothelial cells, and smooth muscle of all patients (<xref ref-type="fig" rid="F3">Fig. 3</xref>), although semiquantitative evaluation showed that their intensities were much stronger in IPF patients than in NSIP patients (<xref ref-type="table" rid="T2">Table 2</xref>). IL-13R&#x003b1;2 showed the same pattern of expression as IL-13R&#x003b1;1 but weaker staining in both patient groups (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F3">Fig. 3</xref>). Neither IL-13R&#x003b1;1 nor IL-13R&#x003b1;2 expression was detected in the four control lung tissues.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>We demonstrated that IL-4 and IL-13 levels were higher in the BAL fluids of NSIP and IPF patients than in that of healthy subjects and that INF-&#x003b3; levels were lowest in the NSIP groups. These findings suggest that there is a predominance of Th2 over Th1 cytokines in the lungs of NSIP patients, as demonstrated in IPF patients of previous studies (<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>). In the present study, the mean IL-13 level was higher in patients than in controls, consistent with the reports of Jakubzick et al. (<xref ref-type="bibr" rid="B4">4</xref>), who demonstrated that IL-13 gene expression was higher in lung biopsies of IPF and NSIP patients. However, in our study, the mean IL-13 level was higher in IPF patients than in NSIP patients, whereas Jakubzick et al. (<xref ref-type="bibr" rid="B24">24</xref>) reported no significant differences in IL-13 gene expression between the two patient groups. In both studies, IL-4 levels were comparable between the two groups.</p><p>In addition, the IL-13 (and not IL-4) level was inversely correlated with physiological derangement, including decreases in DLCO and lung volume. This novel finding (<xref ref-type="fig" rid="F2">Fig. 2</xref>) suggests that IL-13, rather than IL-4, may be associated with functional derangement in the patients with IPF and NSIP.</p><p>Several studies on animal models have suggested a comprehensive role for IL-13, rather than IL-4, in pulmonary fibrosis. Neutralization of IL-13, but not IL-4 alone, attenuated pulmonary fibrosis in a bleomycin-induced pulmonary fibrosis model (<xref ref-type="bibr" rid="B22">22</xref>). In response to fluorescein isothiocyanate exposure, IL-4 (-/-) mice developed fibrosis, whereas IL-13 (-/-) mice were significantly resistant to fibrosis (<xref ref-type="bibr" rid="B23">23</xref>). These results, and the fact that IPF is associated with more fibrotic lung lesion than is NSIP, suggest that IL-13, rather than IL-4, may be responsible for the degree of fibrosis in IIP patients, as seen in our study. Indeed, administrating a chimeric protein, comprising human IL-13 and a truncated version of an exotoxin from <italic>Pseudomonas</italic> (IL13-PE), as a therapeutic agent significantly attenuated fibrosis (<xref ref-type="bibr" rid="B24">24</xref>). IL-13 may induce pulmonary fibrosis directly (<xref ref-type="bibr" rid="B25">25</xref>) or indirectly through TGF (beta)-1 (<xref ref-type="bibr" rid="B26">26</xref>) and several types of MMP (<xref ref-type="bibr" rid="B27">27</xref>).</p><p>Receptor binding chains for IL-13 include IL-13 R&#x003b1;1 and IL-13R&#x003b1;2 (<xref ref-type="bibr" rid="B11">11</xref>). IL-13 R&#x003b1;1 binds IL-13 with low affinity, whereas the co-expression of IL-13R&#x003b1;1 and IL-4R&#x003b1; results in the formation of a high-affinity receptor signaling complex that renders a variety of cells (e.g., mast, eosinophil, endothelial, fibroblast, smooth muscle, and epithelial cells) responsive to IL-13 (<xref ref-type="bibr" rid="B28">28</xref>). In the present study, both IL-13R&#x003b1;1 and IL-13R&#x003b1;2 were expressed in the bronchial epithelial cells, alveolar macrophages, endothelial cells, and smooth muscles and interstitium of all IPF and NSIP patients, consistent with Jakubzick et al. (<xref ref-type="bibr" rid="B4">4</xref>), who found that both proteins were strongly expressed in the interstitium of the lung and that IL-13R&#x003b1;2 was also strongly expressed in the lung epithelium and in mononuclear cells.</p><p>The effects of IL-13 are mediated by a complex receptor system, which includes IL-4R&#x003b1; and IL-13R&#x003b1;1, via STAT6 activation (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). IL-13R&#x003b1;2 has a short cytoplasmic tail without intracellular signaling motifs that bind to STAT6 (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>) thus, this receptor was expected to compete with the IL-4R&#x003b1;-/IL-13R&#x003b1;1 complex and dampen the IL-13-mediated response (<xref ref-type="bibr" rid="B29">29</xref>). At present, however, it is not clear why the greatly increased expression of IL-13R&#x003b1;2, particularly in IPF patients, fails to curtail the profibrotic actions of IL-13. It is possible that the natural antagonism of IL-13R&#x003b1;2 is lost in patients with IIP as a result of post-translational modifications of this decoy receptor. Or perhaps, as a result of these modifications, the IL-13R&#x003b1;2 subunit takes on an abnormal signaling role in IPF. Fichtner-Feigl et al. (<xref ref-type="bibr" rid="B30">30</xref>) recently demonstrated that IL-13 is involved in the activation of the TGF&#x003b2;1 promoter via IL-13R&#x003b1;2. Furthermore, blocking IL-13 R&#x003b1;2 signaling with siRNA led to a down regulation of TGF&#x003b2;1 production and collagen deposition in bleomycin-induced lung fibrosis (<xref ref-type="bibr" rid="B30">30</xref>). This result indicates that IL-13R&#x003b1;2 can augment fibrosis via TGF&#x003b2; modulation, which contradicts other studies (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B29">29</xref>).</p><p>The present study did not directly evaluate the role of IL-13R&#x003b1;2 as a protector against or inducer of fibrosis in IIP. We demonstrated the increased expression of IL-13R&#x003b1;1 and IL-13R&#x003b1;2 in the two types of IIP, and no expression in controls, indicating that both types of receptors are induced in the tissues of people with IIP. However, the intensity of these two receptors was significantly lower in NSIP patients than in IPF patients. Furthermore, IL-13R&#x003b1;1 was strongly expressed in the epithelium, smooth muscle, and alveolar macrophages of both patient groups, whereas IL-13R&#x003b1;2 was only weakly expressed (<xref ref-type="fig" rid="F2">Fig. 2</xref>, <xref ref-type="table" rid="T2">Table 2</xref>), suggesting that differences in the expression of IL-13R&#x003b1;1 and IL-13R&#x003b1;2 may help explain the varying degrees of lung fibrosis between the two conditions. A possible limitation of our study is that the differences in IL-13 values for the BAL fluids of IIP patients and controls (as determined by ELISA) may have been affected by the presence of soluble isoforms of the IL-13 receptor subunits. There are many potential complications for measuring cytokine proteins in whole lung homogenates; for example, the presence of soluble decoy receptors and post-translational modifications of the cytokine proteins can render the proteins undetectable by ELISA. Small numbers of NSIP and IPF in this study also regarded another limitation.</p><p>In conclusion, IL-13 levels were significantly elevated and inversely correlated with DLCO and FVC in both IPF and NSIP patients. Moreover, IL-13R&#x003b1;1 and IL-13R&#x003b1;2 were strongly expressed in the lung tissues of IPF and NSIP patients. However, IL-13 and the two receptors were more strongly expressed in patients with IPF than in those with NSIP. These results suggest that the elevation of IL-13 elevation and the concomitant expression of IL-13R&#x003b1;1 and IL-13R&#x003b1;2 may be associated with the pathogenesis of both IPF and NSIP.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors are indebted to, Myong-ran Lee, and Eunyoung Kim for their excellent technical support throughout the study. The authors express thanks to at least two professional editors, both native speakers of English for their kind editing for grammar and topographic error <ext-link ext-link-type="uri" xlink:href="http://www.textcheck.com">http://www.textcheck.com</ext-link>.</p><p>The DNA samples were generously provided by the Soonchunhyang University, Bucheon Hospital Biobank, a member of the National Biobank of Korea, supported by the Ministry of Health, Welfare and Family Affairs, Republic of Korea.</p></ack><fn-group><fn fn-type="supported-by"><p>This study was supported by a grant from the Korean Health 21 R&#x00026;D project, <funding-source>Ministry of Health &#x00026; Welfare, Republic of Korea</funding-source> (<award-id>01-PJ10-PG6-01GN14-0003</award-id>) and by the <funding-source>Soonchunhyang University</funding-source> Research Fund (# <award-id>20030198</award-id>).</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzenstein</surname><given-names>AL</given-names></name><name><surname>Myers</surname><given-names>JL</given-names></name></person-group><article-title>Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>157</volume><fpage>1301</fpage><lpage>1315</lpage><pub-id pub-id-type="pmid">9563754</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>WA</given-names></name><name><surname>Ramage</surname><given-names>EA</given-names></name><name><surname>Lamb</surname><given-names>D</given-names></name><name><surname>Howie</surname><given-names>SE</given-names></name></person-group><article-title>A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA)</article-title><source>Clin Exp Immunol</source><year>1995</year><volume>101</volume><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">7664490</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majumdar</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Ansari</surname><given-names>T</given-names></name><name><surname>Pantelidis</surname><given-names>P</given-names></name><name><surname>Black</surname><given-names>CM</given-names></name><name><surname>Gizycki</surname><given-names>M</given-names></name><name><surname>du Bois</surname><given-names>RM</given-names></name><name><surname>Jeffery</surname><given-names>PK</given-names></name></person-group><article-title>Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies</article-title><source>Eur Respir J</source><year>1999</year><volume>14</volume><fpage>251</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">10515397</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakubzick</surname><given-names>C</given-names></name><name><surname>Choi</surname><given-names>ES</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name><name><surname>Evanoff</surname><given-names>H</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Puri</surname><given-names>RK</given-names></name><name><surname>Flaherty</surname><given-names>KR</given-names></name><name><surname>Toews</surname><given-names>GB</given-names></name><name><surname>Colby</surname><given-names>TV</given-names></name><name><surname>Kazerooni</surname><given-names>EA</given-names></name><name><surname>Gross</surname><given-names>BH</given-names></name><name><surname>Travis</surname><given-names>WD</given-names></name><name><surname>Hogaboam</surname><given-names>CM</given-names></name></person-group><article-title>Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia</article-title><source>J Clin Pathol</source><year>2004</year><volume>57</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">15113854</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rottoli</surname><given-names>P</given-names></name><name><surname>Magi</surname><given-names>B</given-names></name><name><surname>Perari</surname><given-names>MG</given-names></name><name><surname>Liberatori</surname><given-names>S</given-names></name><name><surname>Nikiforakis</surname><given-names>N</given-names></name><name><surname>Bargagli</surname><given-names>E</given-names></name><name><surname>Cianti</surname><given-names>R</given-names></name><name><surname>Bini</surname><given-names>L</given-names></name><name><surname>Pallini</surname><given-names>V</given-names></name></person-group><article-title>Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis</article-title><source>Proteomics</source><year>2005</year><volume>5</volume><fpage>1423</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">15761959</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gharaee-Kermani</surname><given-names>M</given-names></name><name><surname>Nozaki</surname><given-names>Y</given-names></name><name><surname>Hatano</surname><given-names>K</given-names></name><name><surname>Phan</surname><given-names>SH</given-names></name></person-group><article-title>Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis</article-title><source>Cytokine</source><year>2001</year><volume>15</volume><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">11554783</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Homer</surname><given-names>RJ</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Geba</surname><given-names>GP</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Elias</surname><given-names>JA</given-names></name></person-group><article-title>Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities and eotaxin production</article-title><source>J Clin Invest</source><year>1999</year><volume>103</volume><fpage>779</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">10079098</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilton</surname><given-names>DJ</given-names></name><name><surname>Zhang</surname><given-names>JG</given-names></name><name><surname>Metcalf</surname><given-names>D</given-names></name><name><surname>Alexander</surname><given-names>WS</given-names></name><name><surname>Nicola</surname><given-names>NA</given-names></name><name><surname>Willson</surname><given-names>TA</given-names></name></person-group><article-title>Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>497</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">8552669</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>R</given-names></name><name><surname>Rosa</surname><given-names>L</given-names></name><name><surname>Daines</surname><given-names>M</given-names></name><name><surname>Khurana Hershey</surname><given-names>G</given-names></name></person-group><article-title>Reconstitution of a functional human type II IL-4/IL-13 receptor in mouse B cells: demonstration of species specificity</article-title><source>J Immunol</source><year>2001</year><volume>166</volume><fpage>1716</fpage><lpage>1722</lpage><pub-id pub-id-type="pmid">11160216</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murata</surname><given-names>T</given-names></name><name><surname>Obiri</surname><given-names>NI</given-names></name><name><surname>Puri</surname><given-names>RK</given-names></name></person-group><article-title>Structure of and signal transduction through interleukin-4 and interleukin-13 receptors</article-title><source>Int J Mol Med</source><year>1998</year><volume>1</volume><fpage>551</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">9852261</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>DD</given-names></name><name><surname>Whitters</surname><given-names>MJ</given-names></name><name><surname>Fitz</surname><given-names>LJ</given-names></name><name><surname>Neben</surname><given-names>TY</given-names></name><name><surname>Finnerty</surname><given-names>H</given-names></name><name><surname>Henderson</surname><given-names>SL</given-names></name><name><surname>O'Hara</surname><given-names>RM</given-names><suffix>Jr</suffix></name><name><surname>Beier</surname><given-names>DR</given-names></name><name><surname>Turner</surname><given-names>KJ</given-names></name><name><surname>Wood</surname><given-names>CR</given-names></name><name><surname>Collins</surname><given-names>M</given-names></name></person-group><article-title>The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>2317</fpage><lpage>2324</lpage><pub-id pub-id-type="pmid">9725226</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiaramonte</surname><given-names>MG</given-names></name><name><surname>Mentink-Kane</surname><given-names>M</given-names></name><name><surname>Jacobson</surname><given-names>BA</given-names></name><name><surname>Cheever</surname><given-names>AW</given-names></name><name><surname>Whitters</surname><given-names>MJ</given-names></name><name><surname>Goad</surname><given-names>ME</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>M</given-names></name><name><surname>Donaldson</surname><given-names>DD</given-names></name><name><surname>Grusby</surname><given-names>MJ</given-names></name><name><surname>Wynn</surname><given-names>TA</given-names></name></person-group><article-title>Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response</article-title><source>J Exp Med</source><year>2003</year><volume>197</volume><fpage>687</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">12642601</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliot</surname><given-names>TL</given-names></name><name><surname>Lynch</surname><given-names>DA</given-names></name><name><surname>Newell</surname><given-names>JD</given-names><suffix>Jr</suffix></name><name><surname>Cool</surname><given-names>C</given-names></name><name><surname>Tuder</surname><given-names>R</given-names></name><name><surname>Markopoulou</surname><given-names>K</given-names></name><name><surname>Veve</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name></person-group><article-title>High-Resolution computed tomography features of nonspecific interstitial pneumonia and usual interstitial pneumonia</article-title><source>J Comput Assist Tomogr</source><year>2005</year><volume>29</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">15891504</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>KR</given-names></name><name><surname>Travis</surname><given-names>WD</given-names></name><name><surname>Colby</surname><given-names>TV</given-names></name><name><surname>Toews</surname><given-names>GB</given-names></name><name><surname>Kazerooni</surname><given-names>EA</given-names></name><name><surname>Gross</surname><given-names>BH</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Strawderman</surname><given-names>RL</given-names></name><name><surname>Flint</surname><given-names>A</given-names></name><name><surname>Lynch</surname><given-names>JP</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name></person-group><article-title>Histopathologic variability in usual and nonspecific interstitial pneumonias</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>1722</fpage><lpage>1727</lpage><pub-id pub-id-type="pmid">11719316</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jegal</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Shim</surname><given-names>TS</given-names></name><name><surname>Lim</surname><given-names>CM</given-names></name><name><surname>Do Lee</surname><given-names>S</given-names></name><name><surname>Koh</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>Kim</surname><given-names>WD</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Travis</surname><given-names>WD</given-names></name><name><surname>Kitaichi</surname><given-names>M</given-names></name><name><surname>Colby</surname><given-names>TV</given-names></name></person-group><article-title>Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia</article-title><source>Am J Respir Crit Care Med</source><year>2005</year><volume>171</volume><fpage>639</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">15640368</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>CS</given-names></name><name><surname>Jeon</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Lim</surname><given-names>GI</given-names></name><name><surname>Jeong</surname><given-names>SH</given-names></name><name><surname>Uh</surname><given-names>ST</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Choi</surname><given-names>DL</given-names></name><name><surname>Jin</surname><given-names>SY</given-names></name><name><surname>Kang</surname><given-names>CH</given-names></name></person-group><article-title>Nonspecific interstitial pneumonia/fibrosis: clinical manifestations, histologic and radiologic features</article-title><source>Korean J Intern Med</source><year>1996</year><volume>11</volume><fpage>122</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">8854648</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>CS</given-names></name><name><surname>Chung</surname><given-names>SW</given-names></name><name><surname>Ki</surname><given-names>SY</given-names></name><name><surname>Lim</surname><given-names>GI</given-names></name><name><surname>Uh</surname><given-names>ST</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Choi</surname><given-names>DI</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>DW</given-names></name><name><surname>Kitaichi</surname><given-names>M</given-names></name></person-group><article-title>Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>162</volume><fpage>1162</fpage><lpage>1168</lpage><pub-id pub-id-type="pmid">10988147</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Mukae</surname><given-names>H</given-names></name><name><surname>Kadota</surname><given-names>J</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Ashitani</surname><given-names>J</given-names></name><name><surname>Kohno</surname><given-names>S</given-names></name></person-group><article-title>Increased levels of interleukin-18 in bronchoalveolar lavage fluid of patients with idiopathic nonspecific interstitial pneumonia</article-title><source>Respiration</source><year>2005</year><volume>72</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">15753633</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>S</given-names></name><name><surname>Mukae</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>K</given-names></name><name><surname>Kakugawa</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>N</given-names></name><name><surname>Nakayama</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Kadota</surname><given-names>J</given-names></name><name><surname>Kohno</surname><given-names>S</given-names></name></person-group><article-title>High-BAL fluid concentrations of RANTES in nonspecific interstitial pneumonia compared with usual interstitial pneumonia</article-title><source>Respir Med</source><year>2004</year><volume>98</volume><fpage>945</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">15481270</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>S</given-names></name><name><surname>Mukae</surname><given-names>H</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Kakugawa</surname><given-names>T</given-names></name><name><surname>Sugiyama</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>N</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Kadota</surname><given-names>J</given-names></name><name><surname>Kohno</surname><given-names>S</given-names></name></person-group><article-title>Comparison of BALF concentrations of ENA-78 and IP10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia</article-title><source>Respir Med</source><year>2005</year><volume>99</volume><fpage>1145</fpage><lpage>1151</lpage><pub-id pub-id-type="pmid">16085216</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><collab>American Thoracic Society (ATS) and European Respiratory Society (ERS)</collab><article-title>Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society, and the European Respiratory Society</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>161</volume><fpage>646</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">10673212</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belperio</surname><given-names>JA</given-names></name><name><surname>Dy</surname><given-names>M</given-names></name><name><surname>Burdick</surname><given-names>MD</given-names></name><name><surname>Xue</surname><given-names>YY</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Elias</surname><given-names>JA</given-names></name><name><surname>Keane</surname><given-names>MP</given-names></name></person-group><article-title>Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis</article-title><source>Am J Respir Cell Mol Biol</source><year>2002</year><volume>27</volume><fpage>419</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">12356575</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolodsick</surname><given-names>JE</given-names></name><name><surname>Toews</surname><given-names>GB</given-names></name><name><surname>Jakubzick</surname><given-names>C</given-names></name><name><surname>Hogaboam</surname><given-names>C</given-names></name><name><surname>Moore</surname><given-names>TA</given-names></name><name><surname>Mckenzie</surname><given-names>A</given-names></name><name><surname>Wilke</surname><given-names>CA</given-names></name><name><surname>Chrisman</surname><given-names>CJ</given-names></name><name><surname>Moore</surname><given-names>BB</given-names></name></person-group><article-title>Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>4068</fpage><lpage>4076</lpage><pub-id pub-id-type="pmid">15034018</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakubzick</surname><given-names>C</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name><name><surname>Puri</surname><given-names>RK</given-names></name><name><surname>Hogaboam</surname><given-names>CM</given-names></name></person-group><article-title>Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis</article-title><source>Immunol Res</source><year>2004</year><volume>30</volume><fpage>339</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">15531774</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiaramonte</surname><given-names>MG</given-names></name><name><surname>Donaldson</surname><given-names>DD</given-names></name><name><surname>Cheever</surname><given-names>AW</given-names></name><name><surname>Wynn</surname><given-names>TA</given-names></name></person-group><article-title>An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response</article-title><source>J Clin Invest</source><year>1999</year><volume>104</volume><fpage>777</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">10491413</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Homer</surname><given-names>RJ</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Lanone</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Koteliansky</surname><given-names>V</given-names></name><name><surname>Shipley</surname><given-names>JM</given-names></name><name><surname>Gotwals</surname><given-names>P</given-names></name><name><surname>Noble</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Senior</surname><given-names>RM</given-names></name><name><surname>Elias</surname><given-names>JA</given-names></name></person-group><article-title>Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)</article-title><source>J Exp Med</source><year>2001</year><volume>194</volume><fpage>809</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">11560996</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanone</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Homer</surname><given-names>RJ</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Rabach</surname><given-names>LA</given-names></name><name><surname>Rabach</surname><given-names>ME</given-names></name><name><surname>Shipley</surname><given-names>JM</given-names></name><name><surname>Shapiro</surname><given-names>SD</given-names></name><name><surname>Senior</surname><given-names>RM</given-names></name><name><surname>Elias</surname><given-names>JA</given-names></name></person-group><article-title>Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling</article-title><source>J Clin Invest</source><year>2002</year><volume>110</volume><fpage>463</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">12189240</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akaiwa</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Umeshita-Suyama</surname><given-names>R</given-names></name><name><surname>Terada</surname><given-names>N</given-names></name><name><surname>Suto</surname><given-names>H</given-names></name><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Arima</surname><given-names>K</given-names></name><name><surname>Matsushita</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Furue</surname><given-names>M</given-names></name><name><surname>Hamasaki</surname><given-names>N</given-names></name><name><surname>Ohshima</surname><given-names>K</given-names></name><name><surname>Izuhara</surname><given-names>K</given-names></name></person-group><article-title>Localization of human interleukin 13 receptor in non-haematopoietic cells</article-title><source>Cytokine</source><year>2001</year><volume>13</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">11145846</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Homer</surname><given-names>RJ</given-names></name><name><surname>Elias</surname><given-names>JA</given-names></name></person-group><article-title>Cytokine regulation of IL-13Ralpha2 and IL-13Ralpha1 in vivo and in vitro</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>111</volume><fpage>720</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">12704349</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fichtner-Feigl</surname><given-names>S</given-names></name><name><surname>Strober</surname><given-names>W</given-names></name><name><surname>Kawakami</surname><given-names>K</given-names></name><name><surname>Puri</surname><given-names>RK</given-names></name><name><surname>Kitani</surname><given-names>A</given-names></name></person-group><article-title>IL-13 signaling through the IL-13 alpha(2) receptor is involved in induction of TGF-beta(1) production and fibrosis</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">16327802</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>IL-4, IL-13, and IFN-&#x003b3; levels in the BAL fluids of IPF and NSIP patients and of normal controls. Horizontal bars represent the mean levels of the three groups.</p></caption><graphic xlink:href="jkms-24-614-g001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><p>Correlation between IL-13 levels and FVC (% pred) and DLCO (% pred) in patients with IPF and NSIP. Open and closed circles represent NSIP and IPF patients, respectively. IL-13 showed a significant inverse correlation with FVC (% pred) (r=-0.47, <italic>P</italic>=0.043) and DLCO (% pred) (r=-0.58, <italic>P</italic>=0.014).</p></caption><graphic xlink:href="jkms-24-614-g002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><p>Immunohistochemical analysis of IL-13 and IL-13R&#x003b1;1/IL-13R&#x003b1;2 expression in lung tissues from patients with IPF and from controls. IL-13 was only negligibly expressed in controls (<bold>A</bold>) but was strongly expressed in the smooth muscle (<bold>B</bold>), bronchial epithelium, especially the hyperplastic regenerating epithelium (<bold>C</bold>), alveolar macrophages (<bold>D</bold>), endothelium (<bold>E</bold>), and interstitum (<bold>F</bold>) of IPF patients. IL-13R&#x003b1;1 was strongly expressed by the bronchial epithelium and smooth muscle of IPF patients (<bold>G</bold>). IL-13R&#x003b1;2 was weakly expressed in the same regions of IPF patients (<bold>H</bold>). Magnification: &#x000d7;20 (<bold>A</bold>), &#x000d7;40 (<bold>B</bold>), &#x000d7;100 (<bold>C</bold>, <bold>F</bold>-<bold>H</bold>), and &#x000d7;200 (<bold>D</bold>, <bold>E</bold>).</p></caption><graphic xlink:href="jkms-24-614-g003"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic characteristics, lung function and bronchoalveolar lavage fluid (BALF) profiles of the study subjects</p></caption><graphic xlink:href="jkms-24-614-i001"/><table-wrap-foot><fn><p>Data are presents as mean&#x000b1;SEM.</p><p><sup>*</sup><italic>P</italic>&#x0003c;0.05 compared with normal control; <sup>&#x02020;</sup><italic>P</italic>&#x0003c;0.01 compared with normal control.</p><p>IPF, idiopathic pulmonary fibrosis; CS, current smoker; ES, ex-smoker; NS, never-smoker; TLC, total lung capaciy; FVC, forced vital capacity; DLCO, diffusing capacity of carbon monoxide; NSIP, nonspecific interstitial pneumonia.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Immunostaining for IL-13, IL-13R&#x003b1;1, and IL-13R&#x003b1;2 from IPF, NSIP and normal controls lung specimens</p></caption><graphic xlink:href="jkms-24-614-i002"/><table-wrap-foot><fn><p>Data are presented as - (absent) to +++ (intense) staining.</p><p>IPF, idiopathic pulmonary fibrosis; NSIP, nonspecific interstitial pneumonia.</p></fn></table-wrap-foot></table-wrap></floats-group></article>